The role of tumor-associated macrophages on tumor progression in non-small cell lung carcinoma
Abstract
Aim: Lung
cancer remains the leading cause of cancer-related mortality in all over the
world. Non-small cell lung cancer (NSCLC) is the most frequent type of lung
carcinoma. In the current study, the effects of tumor-associated macrophages
(TAM) on tumor progression and metastasis in NSCLC were investigated.
Materials
and Methods: Eighty NSCLC cases, which were diagnosed in Başkent
University Medical School, Department of Pathology between January 2011 and May
2016 were included into the study. Clinical follow-up findings of the patients were
recorded and CD68 immunohistochemistry was performed to all of them.
Results: Histologically, 36 cases (45%) were squamous cell carcinoma, 36 cases
(45%) were adenocarcinoma, 6 cases (7.5%) were large cell carcinoma, and 2
cases were adenosquamous carcinoma (2.5%). The density of TAM in tumor tissue was
1+ in 28 cases (35%), 2+ in 21 cases (26.3%) and 3+ in 31 (38.8%) cases by
immunohistochemistry. In addition, the density of TAM was 3+ in only 1 (3.1%)
of 32 stage 1 patients, 17 (53.1%) of 32 stage 2 and 13 (81.3%) of 16 stage 3
and 4 patients had 3+ TAM density. The average survival was 39.7±17.4 months,
36.6±17.1 months and 27.3±18.4 months respectively (p<0.05), in the the
patients who had 1+, 2+ and 3+ TAM density.
Conclusion:
In the current study, we detected that the number
of TAM is higher in NSCLC patients who had higher pathological T and TNM stage.
Also, an average survival of the patients who had a higher number of TAM was
shorter than the patients who had a lower number of TAM.
Keywords
Kaynakça
- Travis DW, Brambilla E, Burke AP, Marx A, Nicholson AG. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 4th ed. IARCPress; Lyon;2015:9-26.
- Siegel RL, Miller KD, Jemal A. Cancer statistics 2015. CA Cancer J Clin 2015;65(1):5-29.
- Rothschild SI. Targeted therapies in non-small cell lung cancer—beyond EGFR and ALK. Cancers 2015;7(2):930-49. Mantovani A, Sica A. Macrophages innate immunity and cancer: Balance, tolerance, and diversity. Curr Opin Immunol 2010;22(2):231-7.
- Coffelt SB, Hughes R, Lewis CE. Tumor-associated macrophages; effectors of angiogenesis and tumor progression. Biochim Biophys Acta 2009;1796(1):11-8.
- Noy R, Pollard JW. Tumor-associated macrophages: From mechanisms to therapy. Immunity 2014;41(1):49-61.
- Becker M, Müller CB, De Bastiani MA, Klannt F. The prognostic impact of tumor-associated macrophages and intra-tumoral apoptosis in non-small cell lung cancer. Histol Histopathol 2014;29(1): 21-31.
- Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 2009;86(5):1065-73.
- Forssell J, Oberg A, Henriksson ML, Stenling R, Jun A, Palmqvist R. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res 2007;13(5):1472-9.
Ayrıntılar
Birincil Dil
Türkçe
Konular
-
Bölüm
Araştırma Makalesi
Yazarlar
Merih Tepeoğlu
*
0000-0002-9894-8005
Türkiye
F.zeynep Taştepe
0000-0001-7149-6443
Türkiye
B.handan Özdemir
0000-0002-7528-3557
Türkiye
Yayımlanma Tarihi
1 Haziran 2018
Gönderilme Tarihi
22 Mart 2017
Kabul Tarihi
30 Mayıs 2017
Yayımlandığı Sayı
Yıl 1970 Cilt: 57 Sayı: 2